Pacing: Power in Slowing Down
One of the cornerstones of our annual Advocacy Week program is the EmPOWER M.E. roundtable. Panels of patient advocates, professionals, and scientists share their expertise on topics relevant to the […]
12 events found.
Webinar
Events
-
-
-
-
Probing Functional Autoantibodies in Patients with ME/CFS
Dr. Akiko Iwasaki (Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University) is the first recipient of Solve’s ME/CFS Catalyst Award in support of her study, “Probing Functional Autoantibodies in Patients with ME/CFS.” In this webinar, Dr. Iwasaki will talk to Solve CEO Emily Taylor about the study, which focuses on […]
-
-
Targeting Autophagy: A Clinical Trial of Low-Dose Rapamycin for ME/CFS, Long COVID, and IACCIs
Simmaron Research is the second recipient of Solve’s ME/CFS Catalyst Award in support of its study,” “Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions.” Read a preprint from Phase 1 of the trial here. The study advances an already FDA-approved drug for reducing key symptoms of ME/CFS and Long Covid, repurposing rapamycin […]
-
-
The Unified Platform: Advancing Research Across ME/CFS, Long Covid, and Other Chronic Conditions
Chronic illnesses such as myalgic encephalomyelitis (ME) and Long COVID, which lack clinical biomarkers, present challenges around diagnosis, symptom reporting, and monitoring. That’s why the unhide® Solve Together Unified Platform–which is participant-led with continuous digital data collection–offers some advantages over traditional site-based clinical research models. The easy-to-use, secure platform allows patients to contribute data through […]
-
-
From Mystery to Measurable: The Science Behind the New ME/CFS Blood Test
For the first time, scientists have developed a simple, accurate blood test that can potentially identify Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) — a long-term, debilitating condition that affects millions of patients worldwide. The study (published in the Journal of Translational Medicine), led by the University of East Anglia in partnership with Oxford BioDynamics, […]
-
-
Protecting the Ones You Love: Legal & Insurance Tools for ME/CFS Caregivers
Caring for someone with ME/CFS is an act of deep love–and preparation is one of the most meaningful ways to protect their future. Hosted by Solve M.E. Director of Advocacy […]
-
-
GLP-1 Drugs to Reduce Symptoms in People with ME/CFS and Identify Disease Subgroups
Glucagon-Like Peptide-1 (GLP-1) agonist medications, like semaglutide, are injectable or oral drugs that mimic the natural GLP-1 hormone, which helps regulate insulin levels. Thus, these medicines help control blood sugar in people with Type 2 diabetes and promote substantial weight loss for individuals with a high body mass index (BMI) by slowing digestion, reducing appetite, […]
Free -
The Discovery of Target Antigens for Dysfunctional T Cells in ME/CFS and Long COVID
Dr. Liisa Selin, Dr. Ayano Kohlgruber, and Dr. Roshan Kumar received a Solve ME/CFS Catalyst Award for their study searching for the exact proteins recognized by T-cell receptors from a person with ME/CFS and a person with Long Covid. These disease-associated T cells include “exhausted” CD8+ T cells and “double-positive” CD4+/CD8+ T cells (which are […]
Free -
-
Sequence ME & Long Covid: The Search for ME/CFS and Long Covid Biomarkers and Subtypes
The DecodeME Project is the largest genetic study of ME/CFS conducted to date and has identified eight genetic signals where people with ME/CFS tend to differ from those without, linked […]
-
-
Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS
In 2025, Simmaron Research was the second recipient of Solve’s ME/CFS Catalyst Award in support of its study, “Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions.” The study hypothesizes that mTOR inhibition through rapamycin may address observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and other […]
-
-
“Coffee With a Clinician” in Recognition of Severe M.E. Awareness Month
Solve M.E. is proud to join our hosts from the Bateman Horne Center for a special edition of their program "Coffee with a Clinician" in observance of Severe ME/CFS Awareness Month. Solve Vice President of Scientific Programs Dr. Jessica Maya, along with representatives from Open Medicine Foundation, #MEAction, and the authors of What is Myalgic […]
Free -
-
A Safe, Accessible Treatment for ME/CFS? The Mitochondrial Stabilizer IVO-21 Study
As part of our commitment to advancing science that brings real hope to people living with ME/CFS or Long Covid, Solve has selected Dr. Jay H. Chung (National Institutes of Health) as a recipient of our latest ME/CFS Catalyst Award. Dr. Chung’s groundbreaking study, “Mitochondrial Stabilizer IVO-21 As Therapy for ME/CFS,” is focused on developing […]